EPOCH for Burkitt Lymphoma

Phase-Based Progress Estimates
National Institutes of Health Clinical Center, Bethesda, MD
Burkitt Lymphoma+9 More
EPOCH - Drug
Any Age
All Sexes
Eligible conditions

Study Summary

This study is evaluating whether a combination of chemotherapy drugs can be used to treat cancer.

See full description

Eligible Conditions

  • Burkitt Lymphoma
  • Primary Mediastinal Large B-cell Lymphoma
  • Large Cell Anaplastic Lymphoma
  • Gray Zone Lymphoma
  • Diffuse Large B-Cell Lymphoma (DLBCL)

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Burkitt Lymphoma

Study Objectives

This trial is evaluating whether EPOCH will improve 1 primary outcome and 1 secondary outcome in patients with Burkitt Lymphoma. Measurement will happen over the course of Time of progression.

Day 30
Safety and Toxicity
Time of progression
Overall response and PFS

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Other trials for Burkitt Lymphoma

Trial Design

1 Treatment Group

Arm A
1 of 1
Experimental Treatment

This trial requires 348 total participants across 1 different treatment group

This trial involves a single treatment. EPOCH is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.

Arm AEPOCH + Rituximab every 3 weeks for 6 cycles.
First Studied
Drug Approval Stage
How many patients have taken this drug
Completed Phase 2
FDA approved

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: initiation of study drug until 30 days after treatment
This trial has the following approximate timeline: 3 weeks for initial screening, variable treatment timelines, and roughly initiation of study drug until 30 days after treatment for reporting.

Closest Location

National Institutes of Health Clinical Center - Bethesda, MD

Eligibility Criteria

This trial is for patients born any sex of any age. There are 10 eligibility criteria to participate in this trial as listed below.

Mark “yes” if the following statements are true for you:
The stage and prognosis of patients with MGZL and PMBL can be any stage show original
Patients without systemic chemotherapy may be admitted if they have had prior limited-field radiation therapy, a short course of glucocorticoids and/or cyclophosphamide for an urgent problem at diagnosis. show original
Adults with serum creatinine less than or equal to 1.5 mg/dl or creatinine clearance greater than 60 ml/min, and children with serum CR less than or equal to age-adjusted normal (age 12 to 15 maximum serum creatinine 1.2 mg/dl and age greater than 15 maximum serum creatinine 1.5 mg/dl) have adequate major organ function unless impairment is due to organ involvement by lymphoma or immune-mediated mechanism caused by lymphoma. show original
Patients who are at least 12 years old. show original
lymphoma There are two types of non-Hodgkin's lymphomas that can occur in the mediastinum: mediastinal gray zone lymphoma and primary mediastinal B cell lymphoma. show original
The text states that in order to test for the Bcl-2 protein, tissue blocks from patients treated in extramural sites must be forwarded to the National Cancer Institute within a month of study entry. show original
I tested negative for HIV. show original
This product is not recommended for pregnant or nursing women. show original
The individual does not have any active symptomatic ischemic heart disease, myocardial infarction, or congestive heart failure in the past year show original

Patient Q&A Section

What are the signs of lymphoma, diffuse?

"Lymphoma, diffuse can lead to high levels f plasma proteins, low platelets, low white blood cell levels, low neutrophils levels and anemia. T cell lymphoma presents more with fever, night sweats and night sweats. Tumor sites (lymphadenopathy, bone marrow, intestine, tonsils, eye) are the most common in the United States. Unexplained weight loss, swelling or painful spots occur with Hodgkin lymphoma. Symptoms of acute leukemia depend on disease type. Symptoms are often preceded by nonspecific fevers, chills, tiredness and low white blood cell levels. The most common symptom of acute lymphocytic leukemia is loss of appetite and fatigue." - Anonymous Online Contributor

Unverified Answer

How many people get lymphoma, diffuse a year in the United States?

"A recent survey of lymphoma in 3 US counties using the SEER database revealed a rate of 25 cases per 100,000 per year. This rate is approximately five times greater than the average value for all lymphomas in the US, a more than 400 times greater rate than the average rate for all B-cell lymphomas, and even twice as high as the rate of non-Hodgkin's lymphomas in lymphoma-bearing populations. The fact that such a high rate of disease can persist despite significant improvements in chemotherapy and radiotherapy underscores the need to consider lymphoma as a major public health problem." - Anonymous Online Contributor

Unverified Answer

What is lymphoma, diffuse?

"The presentation of DLBCL, diffuse is characterized by a nonspecific clinical course; the disease responds well to chemotherapy but often relapses, typically after 5-7 years, with excellent overall survival rates of 80-90% under current treatment." - Anonymous Online Contributor

Unverified Answer

What are common treatments for lymphoma, diffuse?

"It's important to take in consideration that due to the different pathological mechanism of NHL cell, their treatments also varies. The majority of the cases are with combination of chemotherapy or monochemotherapy, combined with radiotherapy. Bortezomib and rituximab are used for advanced aggressive NHL. With combination chemotherapy of gemtuzumab ozogamicin, anthracycline and a taxane, an anthracycline backbone treatment can be offered." - Anonymous Online Contributor

Unverified Answer

What causes lymphoma, diffuse?

"The exact cause of diffuse lymphoma remains a mystery. Nevertheless, the likelihood of having an underlying connective tissue disorder, such as Sjögren's syndrome or dermatomyositis, as well as genetic predisposition, may be considered when treating patients with this type of lymphoma." - Anonymous Online Contributor

Unverified Answer

Can lymphoma, diffuse be cured?

"Even after aggressive therapy, some patients with LDLD and DLNB can have persistent disease for long periods of time, usually accompanied by progressive and irreversible complications of these diseases." - Anonymous Online Contributor

Unverified Answer

What is the primary cause of lymphoma, diffuse?

"This review shows that the primary cause of lymphoma in children may be infection rather than malignant neoplastic changes in B cells. This suggests a potential role for rituximab treatment in lymphoma with an undefined primary." - Anonymous Online Contributor

Unverified Answer

What are the chances of developing lymphoma, diffuse?

"Lymphoma, diffuse was not associated with a higher chance of developing chronic, long-term lymphoma. These people had an increased risk of developing solid tumors. Lymphoma, diffuse was not associated with an increased risk of developing a lymphoma that was more aggressive. These patients also had higher rates of B-cell lymphoma. Findings from a recent study deserve further evaluation in the future to determine if further studies are warranted." - Anonymous Online Contributor

Unverified Answer

What is epoch?

"The International Working Group of the European Hodgkin Disease Group stated that the original definition of remission was met by the best of all published criteria, that is, an objective complete radiographic resolution of the disease process, no residual evidence of disease and complete normalization of the tumor markers of tumor cell activity. The definition is used by modern clinical investigators to determine the adequacy of Hodgkin disease clinical trials. In this article we recommend the definition of an objective complete resolution of the disease process, no residual evidence of disease, and normality of the tumor markers of tumor cell activity. The objective criteria of the working group can be used in place of the outdated criteria by any investigator when assessing the adequacy of clinical trials." - Anonymous Online Contributor

Unverified Answer

What are the latest developments in epoch for therapeutic use?

"The advances in immunotherapy are promising in both advanced B-cell lymphomas as well as solid tumors and it is anticipated that these approaches will become more important in the treatment and management of indolent lymphomas. It is anticipated that the targeted inhibition of the programmed death-1 (PD-1) pathway will be of increasing use in selected cases with solid tumors. Immunotherapy is also expected to be the next step in targeted therapy for systemic lupus erythematosus and scleroderma." - Anonymous Online Contributor

Unverified Answer

What is the survival rate for lymphoma, diffuse?

"Survival rates do vary according to the subgroups studied and the treatment strategy used. Survival rates of patients with diffuse large B-cell lymphoma remain poor given the current staging criteria of WHO, Ann Arbor Stage. There is an urgent need for better staging criteria." - Anonymous Online Contributor

Unverified Answer

Has epoch proven to be more effective than a placebo?

"Both EP and placebo improved patient survival and tumor control. However, no clear difference was observed between the groups in terms of time to progression." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
See if you qualify for this trial
Get access to this novel treatment for Burkitt Lymphoma by sharing your contact details with the study coordinator.